Article Text

other Versions

PDF
DAS-driven therapy versus routine care in patients with recent-onset active Rheumatoid Arthritis
  1. Yvonne P M Goekoop-Ruiterman (y.p.m.goekoop{at}lumc.nl)
  1. Leiden University Medical Center, Netherlands
    1. Jeska K de Vries-Bouwstra (jeskadvb{at}xs4all.nl)
    1. VU Medical Center, Netherlands
      1. Pit J S M Kerstens (p.kerstens{at}janvanbreemen.nl)
      1. Jan van Breemen Institute, Netherlands
        1. Markus M J Nielen
        1. Jan van Breemen Institute, Netherlands
          1. Koen Vos (k.vos{at}janvanbreemen.nl)
          1. Jan van Breemen Institute, Netherlands
            1. Dirkjan van Schaardenburg (d.v.schaardenburg{at}janvanbreemen.nl)
            1. Jan van Breemen Institute, Netherlands
              1. Irene Speyer (ispeyer{at}bronovo.nl)
              1. Hospital Bronovo, Netherlands
                1. Patrick E H Seys (pseys{at}lievensberg.nl)
                1. Hospital Lievensberg, Netherlands
                  1. Ferdinand C Breedveld (f.c.breedveld{at}lumc.nl)
                  1. Leiden University Medical Center, Netherlands
                    1. Cornelia F Allaart (c.f.allaart{at}lumc.nl)
                    1. Leiden University Medical Center, Netherlands
                      1. Ben A C Dijkmans (bac.dijkmans{at}vumc.nl)
                      1. VU Medical Center, Netherlands

                        Abstract

                        Objectives: To compare the efficacy of disease activity score (DAS)-driven therapy and routine care in patients with recent-onset rheumatoid arthritis.

                        Methods: Patients with recent-onset rheumatoid arthritis receiving traditional antirheumatic therapy from either the BeSt study[1], a randomized controlled trial comparing different treatment strategies (group A) or 2 Early Arthritis Clinics (group B) were included. In group A, systematic DAS-driven treatment adjustments aimed to achieve low disease activity (DAS ≤2.4). In group B, treatment was left to the discretion of the treating physician. We evaluated functional ability (HAQ), disease activity score in 28 joints (DAS28) and Sharp/van der Heijde radiographic score (SHS).

                        Results: At baseline, patients in group A (n=234) and group B (n=201) had comparable demographic characteristics and a mean HAQ of 1.4. Group A had a longer median disease duration than group B (0.5 vs 0.4 year, p=0.016), a higher mean DAS28 (6.1 vs 5.6, p<0.001), more rheumatoid factor positive patients (66% vs 42%, p<0.001) and more erosive patients (71% vs 53%, p<0.001). After 1 year, the HAQ improvement was 0.7 vs 0.5 (p=0.029), and the percentage in remission (DAS28<2.6) 31% vs 18% (p<0.005) in groups A and B, respectively. In group A, the median SHS progression was 2.0 (expected progression 7.0), in group B, the SHS progression was 1.0 (expected progression 4.4).

                        Conclusions: In patients with recent onset rheumatoid arthritis receiving traditional therapy, systematic DAS-driven therapy results in significantly better clinical improvement and possibly improves the suppression of joint damage progression.

                        Statistics from Altmetric.com

                        Request permissions

                        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.